CCR Down Under is barely over and we now turn our focus back to Belfast for CCR26, June 10th to 12th, 2026.

Over the rest of December we'll announce the the major trial results to be presented at Titanic Belfast.

Our 9th trial is SODa-BIC, an international, multicentre, randomised, double-blind clinical trial evaluating sodium bicarbonate for the treatment of metabolic acidosis in critically ill patients requiring vasopressor support. It is enrolling 500 adult ICU patients with confirmed metabolic acidosis and shock, randomly assigned to receive intravenous sodium bicarbonate or placebo. The intervention targets correction of acidaemia using a protocolised infusion strategy over up to five hours. The primary outcome is major adverse kidney events within 30 days (MAKE30), a composite of death, need for renal replacement therapy, or persistent renal dysfunction. Key secondary outcomes include 30- and 90-day mortality, renal replacement therapy use, and ICU- and vasopressor-free days. SODa-BIC aims to provide definitive evidence to guide the use of bicarbonate therapy in a common yet controversial ICU population.

Registration for CCR26 opens soon!

Added December 30th